Bellicum Pharmaceuticals Initiates Clinical Trial with Novel Controlled Dendritic Cell Immunotherapy in Metastatic Castrate Resistant Prostate Cancer Houston, TX, July 9, 2013 - Bellicum Pharmaceuticals, Inc. announced today it has initiated treatment of the first patient in a study of BPX-201 dendritic cells in combination with activating agent ... (more)
http://www.drugs.com/clinical_trials/bellicum-pharmaceuticals-initiates-clinical-trial-15879.html?
http://www.drugs.com/clinical_trials/bellicum-pharmaceuticals-initiates-clinical-trial-15879.html?
No comments:
Post a Comment